IGF1R and benign prostatic hyperplasia: In cancer clinical trials, IGF1R inhibitors have shown manageable toxicity (albeit with limited clinical benefit against many cancers) (29); thus, they may find utility in BPH, particularly if delivery or activity can be restricted to the prostate.